Cargando…

Sialidase Inhibitors with Different Mechanisms

[Image: see text] Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Keil, Joseph M., Rafn, Garrett R., Turan, Isaac M., Aljohani, Majdi A., Sahebjam-Atabaki, Reza, Sun, Xue-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620260/
https://www.ncbi.nlm.nih.gov/pubmed/36252951
http://dx.doi.org/10.1021/acs.jmedchem.2c01258
_version_ 1784821322007707648
author Keil, Joseph M.
Rafn, Garrett R.
Turan, Isaac M.
Aljohani, Majdi A.
Sahebjam-Atabaki, Reza
Sun, Xue-Long
author_facet Keil, Joseph M.
Rafn, Garrett R.
Turan, Isaac M.
Aljohani, Majdi A.
Sahebjam-Atabaki, Reza
Sun, Xue-Long
author_sort Keil, Joseph M.
collection PubMed
description [Image: see text] Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in biological pathways. Inhibition of sialidases with inhibitors is an important approach for understanding sialidase function and the underlying mechanisms and could serve as a therapeutic approach as well. Transition-state analogues, such as anti-influenza drugs oseltamivir and zanamivir, are major sialidase inhibitors. In addition, difluoro-sialic acids were developed as mechanism-based sialidase inhibitors. Further, fluorinated quinone methide-based suicide substrates were reported. Sialidase product analogue inhibitors were also explored. Finally, natural products have shown competitive inhibiton against viral, bacterial, and human sialidases. This Perspective describes sialidase inhibitors with different mechanisms and their activities and future potential, which include transition-state analogue inhibitors, mechanism-based inhibitors, suicide substrate inhibitors, product analogue inhibitors, and natural product inhibitors.
format Online
Article
Text
id pubmed-9620260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-96202602022-11-01 Sialidase Inhibitors with Different Mechanisms Keil, Joseph M. Rafn, Garrett R. Turan, Isaac M. Aljohani, Majdi A. Sahebjam-Atabaki, Reza Sun, Xue-Long J Med Chem [Image: see text] Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in biological pathways. Inhibition of sialidases with inhibitors is an important approach for understanding sialidase function and the underlying mechanisms and could serve as a therapeutic approach as well. Transition-state analogues, such as anti-influenza drugs oseltamivir and zanamivir, are major sialidase inhibitors. In addition, difluoro-sialic acids were developed as mechanism-based sialidase inhibitors. Further, fluorinated quinone methide-based suicide substrates were reported. Sialidase product analogue inhibitors were also explored. Finally, natural products have shown competitive inhibiton against viral, bacterial, and human sialidases. This Perspective describes sialidase inhibitors with different mechanisms and their activities and future potential, which include transition-state analogue inhibitors, mechanism-based inhibitors, suicide substrate inhibitors, product analogue inhibitors, and natural product inhibitors. American Chemical Society 2022-10-17 2022-10-27 /pmc/articles/PMC9620260/ /pubmed/36252951 http://dx.doi.org/10.1021/acs.jmedchem.2c01258 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Keil, Joseph M.
Rafn, Garrett R.
Turan, Isaac M.
Aljohani, Majdi A.
Sahebjam-Atabaki, Reza
Sun, Xue-Long
Sialidase Inhibitors with Different Mechanisms
title Sialidase Inhibitors with Different Mechanisms
title_full Sialidase Inhibitors with Different Mechanisms
title_fullStr Sialidase Inhibitors with Different Mechanisms
title_full_unstemmed Sialidase Inhibitors with Different Mechanisms
title_short Sialidase Inhibitors with Different Mechanisms
title_sort sialidase inhibitors with different mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620260/
https://www.ncbi.nlm.nih.gov/pubmed/36252951
http://dx.doi.org/10.1021/acs.jmedchem.2c01258
work_keys_str_mv AT keiljosephm sialidaseinhibitorswithdifferentmechanisms
AT rafngarrettr sialidaseinhibitorswithdifferentmechanisms
AT turanisaacm sialidaseinhibitorswithdifferentmechanisms
AT aljohanimajdia sialidaseinhibitorswithdifferentmechanisms
AT sahebjamatabakireza sialidaseinhibitorswithdifferentmechanisms
AT sunxuelong sialidaseinhibitorswithdifferentmechanisms